Investment & Management Team

Advisors
 

Jianzhu Chen
Prof.
Co-Director of the Center for Infection and Immunity, Chinese Academy of Sciences; Professor of the Massachusetts Institute of Technology

Jun Yan
Prof.
Professor of Medicine, Microbiology and Immunology, and Pharmatocology and Toxicology

Lishan Su PhD
Prof.
Prof. of Microbiology & Immunology at UNC-Chaple Hill. Study development and function of human immune system;

Inderjit Singh 
Prof.
Distinguished University Professor of MUSC, Sherman Financial Group Endowed Chair in Neurosciences , Professor of Pediatrics, Biochemistry and Molecular Biology

Ben Gaston 
PhD

Chief, Division of Pediatric Pulmonary, Allergy and Immunology and Professor of Pediatric Medicine. Rainbow Babies & Children's Hospital of University Hospitals / Case Western Reserve University School of Medicine


Wentao Wu 
PhD​
Guest professor of Institute of Materia Medica Chinese Academy of Medical Science; expert on clinical design and safety pharmacology

Gary Rosenthal
PhD

Former R&D VP of RxKinetix, Inc.; Ex-Project Reviewer in NIH.

Xicheng Sun
PhD
Former chief scientist in Replidyne, VP of chemistry and production in Crestone,Inc

Team

Tom Liu
 

Co-founder & CEO

Yanjun Ma
 

Project Director

Rey Fu

Director of Regulatory

Cathy Xia
 

Director of IR

Eric Zhao
 

Investment Manager

Leonard Chang
 

Senior Vice President

Daniel Hu
 

Director of BD

Sara Yang
 

Director of Clinical 

Winne Liao
 

Director of IP & Legal

Doris Yu
 

Investment Manager

Investment Manager

Klaus Xue

Felix Zheng
 

Investment Manager

Director of R&D

Joyce Pak

Mody Zhong
 

Investment Manager

Director of HR

Ping Zhang

Laurel Venture is a life science focused venture capital firm with a focus on venture and growth investment exclusively in therapeutic assets.
We aim to invest in early and mid-stage life science companies in China, Europe and the United States.
Let Life Science Technology Transfer.
We aim to fund companies that can deliver breakthrough medical advances with cutting-edge technology and strong IP profiles. 
Laurel' s team of investors and entrepreneurs share a passion for the transformative power of technology to fulfil the unmet medical need.
Laurel Venture has a team of professionals and external consultants with extensive experience in finance, regulatory, IP, CMC, pre-clinical and clinical operations that engages strategically with our portfolio company Boards, management teams and co-investors to help secure successful corporate partnerships and exits.

Recently, Laurel Venture Capital announced it has completed the acquisition of global rights to the S-Nitrosoglutathione Reductase (GSNOR) assets from Alpine Immune Sciences(NASDAQ:ALPN). GSNOR serves a pivotal role in controlling nitric oxide availability within tissues and plays an important regulatory role in smooth muscle tone, immune function, inflammation and neuronal development. Disregulation of GSNOR has been implicated in disease and studies have shown pharmacologic GSNOR inhibition attenuates lung and systemic inflammation, decreases airspace enlargement in models of chronic obstructive pulmonary disease (COPD) and improves bronchoconstriction in asthma.

About

Immune cell therapy

Immune cell therapy is a treatment of disease through the immune system. Immunotherapy includes immunological checkpoint inhibitors, immune cell therapy, oncolytic viruses, therapeutic antibodies, cancer vaccines, and immune system regulators.

Approach

Gene Therapy 

Gene therapy is a new treatment method by introducing exogenous gene into target cells to correct or compensate for diseases caused by genetic defects and abnormalities . It can treat a variety of diseases including cancer, hereditary diseases, infectious diseases, cardiovascular diseases and autoimmune diseases.

Molecular Targeted Therapy

Molecular targeted therapy selectively delivers the drugs or other active substances to the lesion site, and limits the therapeutic effect or drug effect to specific target cells, tissues or organs without affecting the function of normal cells, tissues or organs. A method for improving the efficacy and reducing toxic side effects. 

Citryll Completes First Closing of a € 15M Series A to Develop its NETosis Inhibiting Antibody

OSS, Netherlands--(BUSINESS WIRE)--http://www.citryll.com/ announced today the first closing of a targeted € 15 million investment round, funded by ModiQuest B.V., BOM Brabant Ventures, BrightGene, and Curie Capital.

2019-09-02
阅读:0 点赞:0

Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Ven

Alpine Immune Sciences announced the completion of the sale and transfer of global rights to the S-Nitrosoglutathione Reductase (GSNOR) assets from Alpine to Laurel Venture Capital.

2019-08-23
阅读:0 点赞:0

Path BioAnalytics Announces New License with Laurel Therapeutics for Targeted Cystic Fibrosis Therap

[August 21st, 2019 BJ]. Chapel Hill, N.C. – Path BioAnalytics Inc. (PBA), a precision medicine company focused on the discovery and development of new treatments for respiratory disease, today announced it has licensed rights to cavosonstat from Laurel Therapeutics, a global clinical-stage biopharmaceutical company headquartered in Hangzhou China.

2019-08-23
阅读:7 点赞:0

加载更多

NEWS

Portfolio

Contact

欧美金融城T2英国中心详情»

地址: 浙江省杭州市余杭区景兴路 
© 2020 Baidu - GS(2019)5218号 - 甲测资字1100930 - 京ICP证030173号 - Data © 长地万方

ADD

hd.hu@laurelventure.com

BP

+86-571-88134917

 

TEL

+86-571-87357695

 

FAX

Room 805, Building #2 British Center,

 

Laurel Venture Capital Ltd

 

China (311121) 

 

European and American Financial City,Yuhang District, Hangzhou